News

Pfizer and Allergan abandon merger after US tax loophole is closed

BMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i2024 (Published 08 April 2016) Cite this as: BMJ 2016;353:i2024
  1. Zosia Kmietowicz
  1. The BMJ

A merger between the United States drug company Pfizer and the Ireland based Allergan has been abandoned “by mutual agreement of the companies” after new tax rules in the US negated the advantages that the deal was supposed to have delivered.1

The deal, which was worth $160bn (£106bn; €150bn), was due to go ahead later this year, and would have created the biggest drug maker by sales. The purchase of Allergan by Pfizer, known as a “tax inversion deal,” would also have led to savings worth an estimated $2bn over three years because, …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe